A Multicenter, Randomized-Controlled, Blinded Trial of Drug-Eluting vs. Bare Metal Stents in De Novo Saphenous Vein Graft Lesions

26 August 2017 (00:00 - 00:00)

Organised by:

Sign in for access options

ESC TV

Sign in for access options

Sign in for access options

About the speaker

Mr Emmanouil Brilakis

Minneapolis Heart Institute Foundation, Minneapolis (United States of America)

6 More presentations in this session

Presentation thumbnail

Comparison of titanium-nitride-oxide-coated versus everolimus-eluting stents in acute coronary syndrome

Doctor P. Tonino (Eindhoven, NL)

Presentation thumbnail

Early strut coverage in patients receiving new-generation drug-eluting stents and its implications for dual antiplatelet therapy: a randomized controlled trial

Professor M. Hong (Seoul, KR)

Presentation thumbnail

Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention and Survival in Patients with Type 1 Diabetes Mellitus

Doctor M. Holzmann (Stockholm, SE)

Presentation thumbnail

Five-year Outcome of a Trial Comparing Second Generation Drug-eluting Stents Using Either Biodegradable Polymer or Durable Polymer

Doctor M. Natsuaki (Saga, JP)

Presentation thumbnail

Clinical outcomes of State-of-the-Art percutaneous coronary revascularization in patients with de novo three vessel disease: Results of the SYNTAX II trial.

Professor J. Escaned (Madrid, ES)

Access the full session

Session thumbnail

Late-Breaking Science in PCI 1

The Event

ESC Congress 2017

26 August - 30 August 2017

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources